People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Synlogic, Inc. | — | Biotechnology | Series C | $186.5M | $3.3B | 2014 |
| Elicio Therapeutics, Inc. | — | Biotechnology | Series B | $105.3M | $392.4M | 2018 |
| Windtree Therapeutics Inc /De/ | — | Biotechnology | Series B | $104.5M | $1.0B | 2019 |
| ProMIS Neurosciences Inc. | — | Biotechnology | Series B | $38.6M | $111.5M | 2021 |
| Lysosomal Therapeutics, Inc. | — | Biotechnology | Series B | $38.0M | $39.7M | 2015 |
| SG DAN Holdings LLC | — | Other | Series A | $14.1M | $213.0M | 2018 |
Daniel Geffken at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Geffken on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barrett | 1 | 18 |
| Isaac Blech | 1 | 14 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Jin Kim | 1 | 13 |
| Edward Mathers | 1 | 12 |
| Hannah Craven | 1 | 12 |
| Bruce Booth | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Laurens Goff | 1 | 11 |
| Clay Thorp | 1 | 10 |
| Chau Khuong | 1 | 9 |
| Robert Ruffolo | 1 | 8 |
| Elaine Jones | 1 | 6 |
| Lewis Geffen | 1 | 6 |
| Nick Leschly | 1 | 5 |
| Evan S. Melrose | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Paul Miller | 1 | 5 |
| James Huang | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.